This study looks at a medicine called migalastat for people with Fabry disease and kidney problems. Fabry disease is a condition caused by changes in a gene called GLA. The study focuses on people with severe kidney issues, where the kidneys can't filter blood well, measured by something called eGFR. Two groups are part of this study: one group with serious kidney issues not on dialysis, and another group needing regular dialysis (a process that removes waste from the blood).

Participants will have a screening visit to see if they can join. Eligible participants will have a second visit within 30 days. The study is for people 18 or older, with a specific type of Fabry disease that responds to migalastat. Participants should not have had kidney transplants or certain other treatments recently.

• The study involves multiple visits and regular dialysis for some participants.
• Participants must be willing to use birth control if they can have children.
• People with certain health conditions or treatments can't join.